Zokardis tablets 7.5mg, No. 28

Arterial hypertension of mild to moderate severity. Acute myocardial infarction with symptoms of heart failure in patients with stable hemodynamic parameters and who did not receive thrombolytic therapy.

Inside, regardless of the time of meals (before, during or after meals), drinking plenty of fluids.

ZokardisЃ 7.5

Arterial hypertension

Patients with normal renal and hepatic function. To achieve optimal blood pressure, treatment begins with 2 tablets. Once a day; in case of insufficient severity of the hypotensive effect, the dose is gradually increased with an interval of 4 weeks.

Usually the effective dose is 4 tablets. Once a day.

The maximum daily dose is 8 tablets, taken once or in 2 doses (4 tablets each).

Patients with impaired water-salt balance. Initial therapy with ACE inhibitors requires correction of salt and / or water deficits, discontinuation of ongoing diuretic therapy within 2-3 days before starting ACE inhibitor administration and begins with a dose of 2 tablets. Zokardis 7.5 1 time per day. If this is not possible, treatment begins with 1 table. Zokardis 7.5 1 time per day.

Patients with impaired renal function or on hemodialysis. In patients with mild renal impairment (Cl creatinine more than 45 ml / min), dose reduction is not required. Patients with moderate and severe renal dysfunction (Cl creatinine less than 45 ml / min) are prescribed 1/2 of the therapeutic dose once a day.

The starting dose for hemodialysis patients is 1/4 the dose used for patients with normal renal function.

Patients with impaired liver function. In patients with mild and moderate liver dysfunction, the initial dose of the drug is half the dose used in patients with normal liver function.

In patients with severe liver dysfunction, Zokardis 7.5 should not be used.

Elderly patients. In elderly patients with normal creatinine clearance, dose adjustment is not required. In elderly patients with Cl creatinine less than 45 ml / min, it is recommended to take 1/2 daily dose. Acute myocardial infarction (as part of combination therapy)

Treatment begins within 24 hours after the onset of the first symptoms of myocardial infarction and continues for 6 weeks.

The following dosage regimen should be applied:

1st and 2nd day: 1 table. Zokardis 7.5 every 12 hours,

3rd and 4th day: 2 tablets. Zokardis 7.5 every 12 hours,

from the 5th day onwards: 4 tab. Zokardis 7.5 every 12 hours

In the case of an excessive decrease in blood pressure at the beginning of treatment or within the first 3 days after myocardial infarction, the initial dose is not increased or the drug is discontinued.

After 6 weeks of admission, therapy can be discontinued in patients without signs of left ventricular failure or heart failure.

For the correction of left ventricular failure or heart failure, as well as arterial hypertension, treatment can be continued for a long time.

Elderly patients. Zokardis 7.5 should be used with caution in patients with myocardial infarction over 75 years old.

ZokardisЃ 30

Arterial hypertension

Patients with normal renal and hepatic function. To achieve optimal blood pressure, treatment begins with 1/2 table. Once a day; in case of insufficient severity of the hypotensive effect, the dose is gradually increased with an interval of 4 weeks.

Usually the effective dose is 1 table. Once a day.

The maximum daily dose is 2 tablets, taken once or in 2 doses (1 table each).

Patients with impaired water-salt balance. Initial therapy with ACE inhibitors requires correction of salt and / or water deficits, discontinuation of ongoing diuretic therapy within 2-3 days prior to taking an ACE inhibitor and begins with a dose of 1/2 table. Zokardis 30 once a day. If this is not possible, treatment begins with 1/4 of the table. Zokardis 30 once a day.

Patients with impaired renal function or on hemodialysis. In patients with mild renal impairment (Cl creatinine more than 45 ml / min), dose reduction is not required. Patients with moderate and severe renal dysfunction (Cl creatinine less than 45 ml / min) are prescribed 1/2 of the therapeutic dose once a day.

The starting dose for hemodialysis patients is 1/4 the dose used for patients with normal renal function.

Patients with impaired liver function. In patients with mild and moderate liver dysfunction, the initial dose of the drug is half the dose used in patients with normal liver function.

In patients with severe liver dysfunction, Zokardis 30 should not be used.

Elderly patients. In elderly patients with normal creatinine clearance, dose adjustment is not required. In elderly patients with Cl creatinine less than 45 ml / min, it is recommended to take 1/2 daily dose.

Acute myocardial infarction (as part of combination therapy)

Treatment begins within 24 hours after the onset of the first symptoms of myocardial infarction and continues for 6 weeks.

The following dosage regimen should be applied:

1st and 2nd day: 1/4 tab. Zokardis 30 every 12 hours,

3rd and 4th day: 1/2 tab. Zokardis 30 every 12 hours,

from the 5th day onwards: 1 table. Zokardis 30 every 12 hours

In the case of an excessive decrease in blood pressure at the beginning of treatment or within the first 3 days after myocardial infarction, the initial dose is not increased or the drug is discontinued.

After 6 weeks of admission, therapy can be discontinued in patients without signs of left ventricular failure or heart failure.

For the correction of left ventricular failure or heart failure, as well as arterial hypertension, treatment can be continued for a long time.

Elderly patients. Zokardis 30 should be used with caution in patients with myocardial infarction over 75 years old.

ZokardisЃ 7.5

in a blister 7 or 14 pcs.; in a pack of cardboard 1 or 2 blisters.

ZokardisЃ 30

in a blister 7 or 14 pcs.; in a pack of cardboard 1 or 2 blisters.

Hypersensitivity to zofenopril and other ACE inhibitors, a history of angioedema associated with treatment with ACE inhibitors, porphyria, severe liver dysfunction, severe renal failure, pregnancy, breastfeeding, age up to 18 years (efficacy and safety have not been established). With caution - primary aldosteronism, bilateral stenosis of the renal arteries, stenosis of the artery of a single kidney, hyperkalemia, condition after kidney transplantation, aortic stenosis, mitral stenosis (with hemodynamic disturbances), idiopathic hypertrophic subaortic stenosis, connective tissue diseases, cerebrovascular diseases, diabetes mellitus insufficiency (proteinuria more than 1 g / day), liver failure, in patients,those who follow a salt-restricted diet or are on hemodialysis, concomitant use with immunosuppressants and saluretics, in the elderly (over 75 years old), psoriasis, in patients with reduced BCC (as a result of diuretic therapy, with restriction of salt intake, hemodialysis, diarrhea and vomiting) - the risk of a sudden and pronounced decrease in blood pressure is increased after using even the initial dose of an ACE inhibitor.